MIAMI--(BUSINESS WIRE)--Dec. 14, 2004--The Alpha-1 Foundation and the Alpha-1 Association have followed Bayer AG’s proposed divestiture of its plasma products business with great interest. The announcement today that an agreement has been signed with NPS BioTherapeutics, Inc. presents an opportunity to continue the remarkable partnership, initially forged with Bayer AG, between the community of individuals with Alpha-1 Antitrypsin Deficiency (Alpha-1) and the primary supplier of specific therapy for this genetic condition.
